Home›Trial›NCT05002127
🔬NCT05002127Phase 2Phase 3ACTIVE NOT RECRUITING

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Study Summary

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Conditions
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Interventions / Drugs
Evorpacept (ALX148)TrastuzumabRamucirumabPaclitaxel
View on ClinicalTrials.gov ↗
Sponsor
ALXO
ALX Oncology
Oncology
D36/100
Study Details
Enrollment127 participants
Primary Completion—
Lead SponsorALX Oncology Inc.
Data Retrieved2026-04-11 02:53:29.486980+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.